Should I buy or sell VolitionRx stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VNRX shares. View VNRX analyst ratings or view top-rated stocks .

What is VolitionRx's stock price target for 2024?

1 brokers have issued 1-year target prices for VolitionRx's stock. Their VNRX share price targets range from $2.00 to $2.00. On average, they predict the company's share price to reach $2.00 in the next year. This suggests a possible upside of 224.0% from the stock's current price. View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts .

How were VolitionRx's earnings last quarter?

VolitionRx Limited (NYSEAMERICAN:VNRX) announced its quarterly earnings results on Monday, March, 25th. The medical research company reported ($0.11) EPS for the quarter. The medical research company had revenue of $0.24 million for the quarter, compared to analysts' expectations of $0.50 million. VolitionRx had a negative trailing twelve-month return on equity of 15,493.47% and a negative net margin of 9,158.31%.

What other stocks do shareholders of VolitionRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRx investors own include Chesapeake Energy (CHKAQ) , Bausch Health Companies (BHC) , Verastem (VSTM) , Exelixis (EXEL) , Rigel Pharmaceuticals (RIGL) , CRISPR Therapeutics (CRSP) , TherapeuticsMD (TXMD) , ADMA Biologics (ADMA) and Bausch Health Companies (BHC) .

How do I buy shares of VolitionRx?

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:VNRX

VolitionRx (VNRX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free VNRX Stock Alerts

$0.62

+0.02 (+3.35%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.61
▼
$0.65
50-Day Range: N/A
52-Week Range: $0.55
▼
$2.10

Volume: 255,788 shs
Average Volume: 176,537 shs
Market Capitalization: $39.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.00

Stock Analysis Analyst Forecasts Chart Earnings Headlines Insider Trades Ownership Short Interest

Get VolitionRx alerts:

VolitionRx MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 224.0% Upside
$2.00 Price Target
Short Interest: Bearish
0.78% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.50) to ($0.33) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.34 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
VolitionRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
VolitionRx has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
0.78% of the outstanding shares of VolitionRx have been sold short.
Short Interest Ratio / Days to Cover
VolitionRx has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in VolitionRx has recently increased by 2.09%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
VolitionRx does not currently pay a dividend.
Dividend Growth
VolitionRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VNRX.

N/A

News and Social Media Coverage

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, VolitionRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
15.40% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 10.14% of the stock of VolitionRx is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for VolitionRx are expected to grow in the coming year, from ($0.50) to ($0.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of VolitionRx is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of VolitionRx is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About VolitionRx Stock (NYSEAMERICAN:VNRX)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

VNRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VNRX Stock News Headlines

March 28, 2024 | seekingalpha.com

VolitionRx Limited (VNRX) Q4 2023 Earnings Call Transcript

March 27, 2024 | finance.yahoo.com

VolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 21, 2024 | msn.com

TELA Bio launches Liquifix surgical devices in the U.S.

March 20, 2024 | finance.yahoo.com

Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan

February 2, 2024 | finance.yahoo.com

Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar

January 6, 2024 | proactiveinvestors.com

VolitionRx has 'compelling plans' to advance veterinary care in 2024

January 4, 2024 | finance.yahoo.com

Volition Issues Business Review 2023

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

January 3, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF), Universal Health (UHS) and VolitionRX (VNRX)

November 14, 2023 | finance.yahoo.com

VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update

November 2, 2023 | finance.yahoo.com

VNRX: Breakthrough Cancer Detection Method Disclosed at ESMO and in a Webinar - preliminary proof of concept work indicates simple blood test should be able to detect several types of cancer, potentially at Stages I & II

November 1, 2023 | msn.com

VolitionRX (VNRX) Price Target Increased by 7.93% to 3.76

October 31, 2023 | msn.com

EF Hutton Initiates Coverage of VolitionRX (VNRX) with Buy Recommendation

October 28, 2023 | markets.businessinsider.com

Cantor Fitzgerald Reaffirms Their Buy Rating on VolitionRX (VNRX)

October 19, 2023 | proactiveinvestors.com

VolitionRx hails study showing Nu.Q NETs promise as biomarker for septic shock

October 19, 2023 | finance.yahoo.com

Measuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic Shock

October 18, 2023 | proactiveinvestors.com

VolitionRx welcomes US Ambassador to Belgium for exclusive tour of research facilities

October 18, 2023 | finance.yahoo.com

US Ambassador Adler visits Belgian Volition

October 16, 2023 | proactiveinvestors.com

VolitionRx to present cancer detection abstracts at European oncology conference

October 16, 2023 | finance.yahoo.com

Volition Presents Three Cancer Detection Abstracts at ESMO 2023

October 13, 2023 | proactiveinvestors.com

VolitionRx holds roundtable on sepsis management

October 13, 2023 | finance.yahoo.com

Volition Publishes Key Opinion Leader Roundtable Report on NETs in Sepsis

October 4, 2023 | proactiveinvestors.com

VolitionRx to unveil new cancer detection method insights at upcoming webinar

October 2, 2023 | finance.yahoo.com

Volition to Reveal New Cancer Detection Method Insights at Upcoming Webinar

September 22, 2023 | msn.com

VolitionRx, Avalo Therapeutic among healthcare movers

September 13, 2023 | finance.yahoo.com

Volition Hosts Key Opinion Leader Roundtable on Sepsis Management

See More Headlines

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/25/2024
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Diagnostics & Research
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:VNRX
Previous Symbol: NYSEMKT:VNRX
CUSIP: N/A
CIK: N/A
Web: www.volitionrx.com
Phone: (646) 650-1351
Fax: 65 32 8172 5651
Employees: 110
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.00
High Stock Price Target: $2.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +224.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,270,000.00
Net Margins: -9,158.31%
Pretax Margin: -9,257.43%
Return on Equity: -15,493.47%
Return on Assets: -149.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.69
Quick Ratio: 0.69

Sales & Book Value

Annual Sales: $310,000.00
Price / Sales: 125.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.05) per share
Price / Book: -12.35

Miscellaneous

Outstanding Shares: 63,180,000
Free Float: 53,450,000
Market Cap: $39.00 million
Optionable: Not Optionable
Beta: 1.59

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Martin Charles Faulkes Ph.D. (Age 80)
Executive Chairman
Comp: $227.63k
Mr. Cameron Reynolds MBA (Age 53)
Founder, CEO, President & Director
Comp: $538.66k
Dr. Jacob Vincent Micallef MBA (Age 68)
Ph.D., Chief Scientific Officer
Comp: $571.55k
Mr. Nicholas Plummer (Age 53)
Group General Counsel
Mr. Gael Forterre M.B.A. (Age 42)
Chief Commercial Officer
Ms. Sharon Ballesteros
U.S. Head of Quality & Development Process
Mr. Rodney Gerard Rootsaert LLB (Age 53)
Corporate Secretary
Comp: $126.23k

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

VNRX Stock Analysis - Frequently Asked Questions

Should I buy or sell VolitionRx stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VNRX shares.
View VNRX analyst ratings or view top-rated stocks.
What is VolitionRx's stock price target for 2024?: 1 brokers have issued 1-year target prices for VolitionRx's stock. Their VNRX share price targets range from $2.00 to $2.00. On average, they predict the company's share price to reach $2.00 in the next year. This suggests a possible upside of 224.0% from the stock's current price.
View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts.
How were VolitionRx's earnings last quarter?: VolitionRx Limited (NYSEAMERICAN:VNRX) announced its quarterly earnings results on Monday, March, 25th. The medical research company reported ($0.11) EPS for the quarter. The medical research company had revenue of $0.24 million for the quarter, compared to analysts' expectations of $0.50 million. VolitionRx had a negative trailing twelve-month return on equity of 15,493.47% and a negative net margin of 9,158.31%.

What other stocks do shareholders of VolitionRx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), CRISPR Therapeutics (CRSP), TherapeuticsMD (TXMD), ADMA Biologics (ADMA) and Bausch Health Companies (BHC).
How do I buy shares of VolitionRx?: Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:VNRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial